Lupin Healthcare, the UK-based wholly owned subsidiary of Lupin Limited (Lupin) has announced that following Marketing Authorisation earlier this year, it has launched Luforbec (beclometasone/formoterol) 100/6 dose pressurised metered dose inhaler (pMDI), making it available now to patients in the UK, with the potential to offer cost savings for the NHS.
Luforbec is indicated for the treatment of adult asthma and for the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD). Luforbec has the same licensed indications as Fostair® 100/6 pMDI, the same active ingredients, an extra fine formulation, and similar device characteristics.
In the 12 months to May 2021, the NHS spent over £177 million on Fostair® 100/6 pMDI. Luforbec will offer a cost saving of £8.80 per prescription.
Respiratory diseases affect one in five people. It is the third biggest cause of death in the UK and is a clinical priority for the NHS. In the UK, around 5.4 million people are currently receiving treatment for asthma, which is equivalent to one in every 12 adults.
An estimated 1.2 million people are also living with COPD. Asthma and COPD place a heavy cost burden on the NHS, estimated at £3 billion and £1.9 billion per year, respectively.
Ben Ellis, General Manager, Lupin Healthcare UK, said: “We are extremely pleased Luforbec is now available in the UK offering a treatment alternative for healthcare professionals at a reduced cost.”
Darush Attar-Zadeh, Respiratory Lead Pharmacist, North Central London Clinical Commissioning Group (Barnet Borough), said: “I welcome the availability of an alternative pMDI option licensed with a spacer for my patients.”